Mechanism and classification
What is Sermorelin?
Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone; it stimulates the anterior pituitary to release GH and has been studied for GH deficiency and aging-related GH decline. Its molecular weight is approximately 3,357.9 Da. Sermorelin acetate (Geref) held FDA approval for pediatric GH deficiency until 2008.[1][2]
What does Sermorelin do to the body?
Sermorelin binds GHRH receptors in the anterior pituitary, stimulating synthesis and pulsatile release of endogenous growth hormone; downstream effects include IGF-1 elevation and associated anabolic signaling.[6] In the Vitiello 2001 aging study, 5-6 months of bedtime sermorelin elevated IGF-1 by approximately 35%, reduced visceral body fat, increased lean body mass by approximately 5% on DEXA, and improved psychomotor processing speed by 5-7%.[4]
Is Sermorelin a steroid?
No. Sermorelin is a peptide hormone analog — a 29-amino-acid chain — not a steroid. It operates on the GHRH receptor (a G protein-coupled receptor), not via steroid hormone receptors.[6] The two structural classes are completely distinct: steroids are lipid-derived four-ring carbon molecules; sermorelin is an amino-acid polypeptide.
Is sermorelin a peptide?
Yes. Sermorelin is a 29-amino-acid synthetic peptide — specifically a truncated analog of the 44-residue endogenous GHRH, retaining full biological activity at the GHRH receptor.[6] Its very short plasma half-life of approximately 4.3 minutes via IV confirms its susceptibility to proteolytic degradation in plasma, which is characteristic of short peptides.[7]
How does sermorelin work?
Sermorelin binds and activates the pituitary GHRH receptor (GHRHR), stimulating cAMP-mediated transcription of GH mRNA and subsequent pulsatile GH secretion; it preserves pituitary reserve unlike exogenous GH.[6] The cAMP signal activates PKA, which phosphorylates CREB, inducing Pit-1 transcription factor synthesis and driving GH gene expression in pituitary somatotrophs.[6]
Dosage and administration
How much sermorelin per day?
Published adult studies employ doses ranging from approximately
14 mcg/kg (~1 mg) at bedtime (Vitiello 2001 aging study)[4] to 1 mg twice daily (Koutkia 2004 JAMA RCT).[10] Pediatric GHD trials used 30 mcg/kg at bedtime[2] and 20 mcg/kg twice daily.[3] These are documented research-population doses, not recommendations for any individual.How many days a week do you take sermorelin?
Published protocols typically employ daily subcutaneous administration. The Vitiello 2001 aging study and the Geref pediatric multicenter trial both used once-daily bedtime dosing.[2][4] Evening dosing to align with endogenous GH pulsatility is the most common timing rationale across trials; 5-days-on/2-days-off cycling appears in practice literature but is not the primary published protocol.
Why take sermorelin at night?
Endogenous GH secretion is highest during slow-wave sleep; evening sermorelin administration is designed to amplify the physiological nocturnal GH pulse.[8] A Kerkhofs 1993 study (American Journal of Physiology) showed GHRH bolus at
0.3 mcg/kg during late sleep produced a nearly 10-fold increase in slow-wave sleep in the third REM period.[8] All major adult therapeutic sermorelin trials used bedtime dosing.[2][4][10]Where to inject sermorelin?
Subcutaneous injection into abdominal, thigh, or deltoid adipose tissue is the route used in clinical trials.[4][10] All major sermorelin clinical trials used subcutaneous administration as the primary route. Intramuscular administration has been studied but appears less frequently in the literature. Intravenous routes were used only in pharmacokinetic characterization studies.[7][8]
How long does it take for sermorelin to work?
Acute GH pulse is detectable within 30-60 minutes of injection in pharmacokinetic studies.[7][8] Functional outcomes (body composition, sleep) emerge over 4-12 weeks of continuous administration in trials: the Vitiello 2001 study measured outcomes at 5-6 months;[4] the Thorner 1996 pediatric study showed accelerated height velocity by 6 months;[2] the Koutkia 2004 JAMA RCT measured body composition at 12 weeks.[10]
How long does sermorelin stay in your system?
Sermorelin has a very short plasma half-life of approximately
4.3 ± 1.4 minutes via IV (Soule 1994).[7] The GH pulse induced by sermorelin peaks at 30-60 minutes and returns to baseline within 3-4 hours. The compound itself is cleared from plasma within minutes; downstream IGF-1 elevation persists longer given IGF-1's ~12-15 hour serum half-life.Safety and side effects
Is sermorelin safe?
Clinical trials characterize sermorelin as generally well-tolerated; serious adverse events are rare; injection-site reactions and transient headache are the most commonly reported findings.[14] The Geref multicenter pediatric trial (110 children, 12 months) found no adverse metabolic changes, normal fasting glucose, and appropriate IGF-I levels.[2] Safety characterization always derives from a specific study population at a specific dose.
What are the downsides of Sermorelin?
Reported adverse effects in studies include injection-site reactions (erythema, pruritus), headache, flushing, dizziness, nausea, arthralgia, and peripheral edema.[14] Subcutaneous bioavailability is less than 4%, so injection is the only effective administration route.[14] One aging study noted a small worsening of subjective sleep quality scores despite IGF-1 elevation — a finding of unclear mechanism.[4]
Are there long-term side effects of Sermorelin?
Long-term safety data in humans is limited; Walker 2006 reported sustained tolerability in the 5-6 month Vitiello aging study and the 12-month Geref pediatric trials.[5][2][16] Extended placebo-controlled studies beyond 12 months are absent from the published literature since the 2008 Geref market withdrawal. The theoretical safety advantage of preserved pituitary feedback — preventing supraphysiological GH/IGF-1 — distinguishes sermorelin from exogenous GH.[5]
Who should not use Sermorelin?
Studies exclude subjects with active malignancy, hypothyroidism, or hypersensitivity to GHRH analogs.[2][14] Hypothyroidism can blunt pituitary GH response to GHRH stimulation. Athletes subject to WADA code cannot use sermorelin without a Therapeutic Use Exemption: it is classified S2 (Prohibited at all times).[1] This is a summary of research exclusion criteria, not a clinical prescribing checklist.
What not to mix with Sermorelin?
Glucocorticoids may blunt GH response by increasing hypothalamic somatostatin tone.[13] The Sigalos 2017 study observed blunted IGF-1 response in subjects using aromatase inhibitors or tamoxifen concurrently with the combination secretagogue protocol.[9] Insulin and thyroid hormones can alter IGF-1 dynamics; co-administration with any GH-axis-active compound warrants evaluation in the research context.[13]
Efficacy and outcomes
Does sermorelin work?
Multiple placebo-controlled trials demonstrate statistically significant GH and IGF-1 elevation. Walker 2006 reported improved sleep quality and body composition markers in adult subjects.[5] The Koutkia 2004 JAMA RCT (n=31) showed significant IGF-1 elevation (104 vs 6 ng/mL placebo, P=0.004) and body composition improvements.[10] The Geref multicenter pediatric trial showed 74% favorable response in 110 children in year one.[2]
Does sermorelin burn belly fat?
Elevated GH/IGF-1 from GHRH stimulation is associated with reduced visceral adipose tissue in multiple trials. The Vitiello 2001 aging study showed approximately 5% reduction in body fat, primarily visceral abdominal fat.[4] The Koutkia 2004 JAMA RCT showed 19.2 cm² VAT decrease versus 2.3 cm² increase in controls.[10] Direct fat-burning causality is dose- and duration-dependent and was measured in specific research populations.
Does sermorelin help with weight loss?
Indirect evidence via GH/IGF-1-mediated lipolysis: controlled studies show reduced fat mass in some cohorts, with the Vitiello 2001 aging study showing ~5% body fat reduction, primarily visceral,[4] and the Koutkia 2004 JAMA RCT showing trunk fat reduction of 0.4 kg versus +0.2 kg placebo.[10] Direct weight-loss as a primary studied endpoint is not the framing of most sermorelin trials.
What does sermorelin do for men?
In male cohort studies, elevated IGF-1 from sermorelin administration correlates with lean mass preservation and, in some trials, testosterone-adjacent changes. The Sigalos 2017 study in 14 hypogonadal men showed IGF-1 increase from 159.5 to 239.0 ng/mL (P<0.0001) and significant testosterone and free testosterone increases over 134 days.[9] The Vitiello 2001 adult cohort showed lean mass increase and body fat reduction in older adults including men.[4]
Can women take sermorelin?
Female subjects appear in multiple published trials; GH/IGF-1 responses are generally present. Estrogen status significantly modulates the response: in the Vitiello 2001 study, non-estrogen replacement therapy women showed approximately 30% IGF-1 increase and 5% body fat reduction, while estrogen replacement therapy women showed vigorous GH response with less than 10% IGF-1 increment — due to hepatic GH resistance from oral estrogen's first-pass effect.[4][18]
Does sermorelin increase testosterone?
Sermorelin acts on the GH/IGF-1 axis, not directly on the HPG axis; direct testosterone elevation is not consistently demonstrated across the literature. The Sigalos 2017 study of hypogonadal men on testosterone therapy — using a combination secretagogue protocol that included sermorelin — showed significant testosterone and free testosterone increases, possibly via GH/IGF-1 androgen interactions.[9] Isolated sermorelin-only testosterone data is limited.
Regulatory and comparative
Is sermorelin FDA approved?
Sermorelin acetate (Geref) held FDA approval for pediatric GH deficiency until 2008 voluntary market withdrawal; it is not currently FDA-approved for any indication but remains active in research literature.[1] The withdrawal was a manufacturing decision by EMD Serono, not a safety recall. The FDA PCAC reviewed sermorelin in October 2024 as a nominated bulk drug substance for the 503A/503B compounding framework.[1]
Is sermorelin legal?
Sermorelin is prescription-only in the US; it is not a controlled substance in most countries.[1] It is prohibited by WADA/USADA in competitive sports under S2 (Peptide Hormones) — prohibited in-competition and out-of-competition.[1] Compounding pharmacies may prepare sermorelin under 503A provisions with a patient-specific prescription. Regulatory status varies internationally.
Why is Sermorelin banned?
USADA and WADA prohibit Sermorelin under S2 peptide hormones due to its GH-stimulating activity and performance enhancement potential.[1] The compound was not banned from the US market by the FDA — it was voluntarily withdrawn in 2008 by its manufacturer due to discontinuation of the active pharmaceutical ingredient, not safety concerns. Anti-doping prohibition and market withdrawal are separate regulatory acts with separate causes.
What is safer, sermorelin or HGH?
Because Sermorelin stimulates endogenous GH release through pituitary feedback mechanisms, it preserves natural GH pulsatility and auto-regulation; exogenous HGH bypasses pituitary feedback, potentially creating supraphysiological GH/IGF-1 states.[5] The Stanley 2011 JCEM trial confirmed GHRH analog administration increased GH pulsatility without impairing insulin sensitivity, unlike exogenous rhGH.[11] This is a mechanistic and theoretical safety distinction; it does not mean sermorelin is without adverse event risk.
What is the sermorelin vs ipamorelin difference?
Sermorelin is a GHRH analog acting on GHRHR; ipamorelin is a ghrelin mimetic acting on GHS-R1a. Both elevate GH but via distinct receptor pathways — combinatorial protocols are studied in some trials.[15][9] Ipamorelin is notable for GH selectivity without cortisol or ACTH elevation, unlike less selective GHRPs.[15] The pathways are mechanistically independent and synergistic.
Is sermorelin like tirzepatide?
Mechanistically distinct: Sermorelin stimulates GH via GHRH receptor agonism; tirzepatide acts on GIP and GLP-1 receptors to modulate insulin and satiety.[6] Different receptor systems, different physiological axes, different research applications. The two compounds have no mechanistic overlap at their primary receptor targets.
RESEARCH FRAMING
All answers on this page are editorial summaries of published peer-reviewed research. This is not a clinical consultation. This site does not sell, prescribe, or recommend sermorelin. Not a clinic, not a vendor, not a prescriber.